Pharma News

(9th October, 2014); Medpro Pharmaceutica (Pty) Ltd - a subsidiary company of Cipla Medpro, the third largest pharmaceutical company in South Africa , yesterday announced that it has entered into a collaboration with Teva Pharmaceuticals (Pty) Ltd, an affiliate of Teva Pharmaceutical Industries Ltd (Teva) - the largest generic pharmaceutical manufacturer in the world with a presence in about 60 countries and approximately 45,000 dedicated employees worldwide. The collaboration is restricted to the territory of South Africa.

(7th October, 2014); Now in the near future, you may not see liquid orals in plastic containers because central government prohibits use of Polyethylene Terephthalate or Plastic containers for primary packaging of drug formulations in certain cases.

(6th October, 2014; Business Wire India); Galderma, a global healthcare company focused on dermatology, today announced that it has initiated a Phase II clinical trial of a novel muscle relaxant in the United States. The study is investigating the safety and efficacy of Galderma’s internally developed liquid formulation of botulinum toxin in the setting of aesthetic dermatology and cosmetic surgery and will add to the existing Galderma neurotoxin franchise.

(6th October, 2014); Novartis announced today that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab), in Phase I/II trials of patients with non-small cell lung cancer (NSCLC).

[adsense:336x280:8701650588]

(1st October, 2014); Think before prescribing broad spectrum antibiotics in children below 2 years of age. Researchers from Philadelphia published a report on last Monday states that the use of broad-spectrum antibiotics by children before the age of 24 months was associated with increased risk of obesity in early childhood.

(30th September, 2014; Business Wire India); Apollo Hospitals and Sanofi today announced their decision to collaborate on the expansion of Apollo Sugar Clinics, which provide integrated diabetes care programs in India. Through this collaboration, Apollo and Sanofi plan to leverage their respective expertise in diabetes to provide patients with access to comprehensive educational resources, treatment and care programs that can help patients better manage their diabetes. The first wave of this collaboration will focus on the establishment of 50 Apollo Sugar Clinics.

(30th September, 2014; Business Wire India); For the Maharashtra government, addressing health issues ranks high on its list of priorities and the same is reflected through various policy interventions, innovative steps and strategies implemented to provide quality healthcare for all.

(30th September, 2014; Business Wire India); Fortis Healthcare announced on last friday (26th sept) that Fortis Mulund, one of its major hospitals in Mumbai has been conferred the prestigious British Medical Journal (BMJ) Award for ‘The Medical Team of the Year 2014.’ The honour was bestowed on the hospital for its outstanding “Antibiotic Review Program – and Antibiotic Restriction Policy.”

(30th September, 2014; Business Wire India); Fortis Healthcare has been awarded the prestigious 2014 ‘Porter Prize, for Value Based Healthcare’. The prize was given in recognition of the company’s outstanding performance in the industry and for redefining the idea of patient care and fundamentally challenging the economic models within the industry.

(20th September, 2014; Business Wire India); Boehringer Ingelheim obtains exclusive global rights for development and commercialisation of CureVac’s investigational therapeutic cancer vaccine CV9202CV9202 is based on CureVac’s mRNA technology (RNActive®) Clinical investigation of CV9202 will be initiated in at least two different lung cancer treatment settings, in combination with Boehringer Ingelheim’s afatinib* and in the chemo-radiation setting. The in-licensing of this investigational cancer compound adds a highly innovative new approach to Boehringer Ingelheim’s lung cancer development portfolio.